Cargando…

Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies

Tyrosine kinase inhibitors (TKIs) have emerged as a targeted therapy of interest for the treatment of systemic sclerosis (SSc). Recently, several groups have performed pilot or “proof-of-concept” studies to determine the feasibility of this approach for the treatment of the cutaneous and pulmonary m...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Jessica, Spiera, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195539/
https://www.ncbi.nlm.nih.gov/pubmed/22013450
http://dx.doi.org/10.1155/2011/842181
_version_ 1782214137117409280
author Gordon, Jessica
Spiera, Robert
author_facet Gordon, Jessica
Spiera, Robert
author_sort Gordon, Jessica
collection PubMed
description Tyrosine kinase inhibitors (TKIs) have emerged as a targeted therapy of interest for the treatment of systemic sclerosis (SSc). Recently, several groups have performed pilot or “proof-of-concept” studies to determine the feasibility of this approach for the treatment of the cutaneous and pulmonary manifestations of this multisystem disease. The conclusions drawn by these different studies have been conflicting, and some controversy has arisen as to whether tyrosine kinase inhibition is a treatment approach worthy of continued study. This paper summarizes this research to date with emphasis on the challenges in interpreting proof-of-concept studies in this patient group.
format Online
Article
Text
id pubmed-3195539
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31955392011-10-19 Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies Gordon, Jessica Spiera, Robert Int J Rheumatol Review Article Tyrosine kinase inhibitors (TKIs) have emerged as a targeted therapy of interest for the treatment of systemic sclerosis (SSc). Recently, several groups have performed pilot or “proof-of-concept” studies to determine the feasibility of this approach for the treatment of the cutaneous and pulmonary manifestations of this multisystem disease. The conclusions drawn by these different studies have been conflicting, and some controversy has arisen as to whether tyrosine kinase inhibition is a treatment approach worthy of continued study. This paper summarizes this research to date with emphasis on the challenges in interpreting proof-of-concept studies in this patient group. Hindawi Publishing Corporation 2011 2011-10-13 /pmc/articles/PMC3195539/ /pubmed/22013450 http://dx.doi.org/10.1155/2011/842181 Text en Copyright © 2011 J. Gordon and R. Spiera. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Gordon, Jessica
Spiera, Robert
Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies
title Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies
title_full Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies
title_fullStr Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies
title_full_unstemmed Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies
title_short Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies
title_sort tyrosine kinase inhibitors in the treatment of systemic sclerosis: the difficulty in interpreting proof-of-concept studies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195539/
https://www.ncbi.nlm.nih.gov/pubmed/22013450
http://dx.doi.org/10.1155/2011/842181
work_keys_str_mv AT gordonjessica tyrosinekinaseinhibitorsinthetreatmentofsystemicsclerosisthedifficultyininterpretingproofofconceptstudies
AT spierarobert tyrosinekinaseinhibitorsinthetreatmentofsystemicsclerosisthedifficultyininterpretingproofofconceptstudies